These results indicate that the IFN-inducible CXCR3 ligands show differences in their anti-tumor effects in a mouse tumor model and suggest that the differences are related to the sensitivity to the chemokine-cleaving enzyme DPP4 expressed in tumor tissues. This evidence concerns the gene DPP4 and neoplasm.